Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase

Gastroenterology

Volumn 138, Issue 3, 2010, Pages 1112-1122

  Ahmed Belkacem, Abdelhakim ^a   Ahnou, Nazim ^a   Barbotte, Laetitia ^a   Wychowski, Czeslaw ^b   Pallier, Coralie ^a,c   Brillet, Rozenn ^a   Pohl, Ralf Torsten ^d   Pawlotsky, Jean Michel ^a,e  

^a INSERM U955   (France)

^b INSTITUT DE BIOLOGIE DE LILLE   (France)

^c BICÊTRE HOSPITAL   (France)

^d Madaus AG   (Germany)

^e HENRI MONDOR HOSPITAL   (France)

Author keywords

Enzyme Assay; Hepatitis C Virus; Polymerase Inhibitor; Silibinin

Indexed keywords

DIHYDROGEN SUCCINATE; ISOSILIBININ A; ISOSILIBININ B; PROTEINASE; RNA POLYMERASE; SILIBININ; SILIBININ A; SILIBININ B; SILICRISTIN; SILIDIANIN; SILYMARIN; SUCCINIC ACID; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME ASSAY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; ISOMER; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS STRAIN;

EID: 77449092252     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.11.053     Document Type: Article

References (32)

1. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 36 (2002) S21-S29
2. Pawlotsky J.M. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 59 (2003) 1-11
3. Chevaliez S., and Pawlotsky J.M. Interferons and their use in persistent viral infections. Handb Exp Pharmacol (2009) 203-241
4. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
5. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
6. Hadziyannis S.J., Sette Jr. H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
7. Pawlotsky J.M., Chevaliez S., and McHutchison J.G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132 (2007) 1979-1998
8. Hezode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360 (2009) 1839-1850
9. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360 (2009) 1827-1838
10. Kwo P., Lawitz E., McCone J., et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C. J Hepatol 50 Suppl (2009) S4
11. Pawlotsky J.M. Therapy of hepatitis C: from empiricism to eradication. Hepatology 43 Suppl (2006) S207-S220
12. Flisiak R., Feinman S.V., Jablkowski M., et al. The cyclophilin inhibitor Debio-025 combined with PEG IFN-alpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49 (2009) 1460-1468
13. Flisiak R., Horban A., Gallay P., et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47 (2008) 817-826
14. Rossignol J.F., Elfert A., El-Gohary Y., et al. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136 (2009) 856-862
15. Simanek V., Kren V., Ulrichova J., et al. Silymarin: what is in the name ... ?. An appeal for a change of editorial policy. Hepatology 32 (2000) 442-444
16. Gazak R., Walterova D., and Kren V. Silybin and silymarin: new and emerging applications in medicine. Curr Med Chem 14 (2007) 315-338
17. Kroll D.J., Shaw H.S., and Oberlies N.H. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 6 (2007) 110-119
18. Polyak S.J., Morishima C., Shuhart M.C., et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized silymarin. Gastroenterology 132 (2007) 1925-1936
19. Hruby K., Csomos G., Fuhrmann M., and Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol 2 (1983) 183-195
20. Ferenci P., Scherzer T.M., Kerschner H., et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 135 (2008) 1561-1567
21. Ishida T., Suzuki T., Hirashima S., et al. Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole. Bioorg Med Chem Lett 16 (2006) 1859-1863
22. Summa V. VX-950 (Vertex/Mitsubishi). Curr Opin Investig Drugs 6 (2005) 831-837
23. Inchauspe G., Zebedee S., Lee D.H., et al. Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci USA 88 (1991) 10292-10296
24. Taremi S.S., Beyer B., Maher M., et al. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci 7 (1998) 2143-2149
25. Wakita T., Pietschmann T., Kato T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (2005) 791-796
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
27. Lohmann V., Korner F., Koch J., et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
28. Zhong J., Gastaminza P., Cheng G., et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102 (2005) 9294-9299
29. Lindenbach B.D., Evans M.J., Syder A.J., et al. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
30. Payan C., Roudot-Thoraval F., Marcellin P., et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 12 (2005) 405-413
31. Al Ashgar H., Helmy A., Khan M.Q., et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med 29 (2009) 4-14
32. Hawke RL, Schrieber SJ, Soule TA, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol In press.